Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025.
Tuesday, January 21, 2025
Evolus projects robust 2025 growth with upcoming product launches
Evolus, Inc. (NASDAQ: NASDAQ:EOLS), a global performance beauty company, has released preliminary unaudited financial results for the fourth quarter and full-year 2024, indicating significant growth. The company reported a 30% increase in net revenue for Q4 2024, totaling $79.0 million, and a 32% rise for the full year, reaching $266.3 million. These figures align with the top end of Evolus's guidance and mark the fifth consecutive year of exceeding 30% revenue growth. With a current market capitalization of $665.51 million and an impressive gross profit margin of 69.94%,
Looking ahead, Evolus anticipates a 30% to 33% increase in net revenue for 2025, projecting between $345 million to $355 million. This forecast includes contributions from the upcoming launch of Evolysse™ Form and Evolysse™ Smooth, two injectable hyaluronic acid (HA) gels expected to account for 8-10% of the total revenue for 2025. Non-GAAP operating expenses for the year are estimated to be between $230 million and $240 million.
Evolus's growth trajectory is further highlighted by an increase in accounts purchasing its flagship product, Jeuveau®, with approximately 830 new accounts in Q4 2024, and over 2,900 new accounts throughout the year. The company's consumer loyalty program, Evolus Rewards, also saw a 40% growth in enrollment, ending the year with roughly 1.1 million consumers.
InMed Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's
INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's
Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')
mRNA profile showed a reduction of several key neuroinflammatory genes in the brain
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression.
Trump revokes Biden’s executive order on addressing AI risks
President Donald Trump has revoked a 2023 executive order signed by former President Joe Biden that sought to reduce the risks that AI poses to consumers, workers, and national security. Biden’s order required developers of AI systems that pose risks to U.S. national security, the economy, public health or safety to share the results of safety tests with the U.S. government before they were released to the public, though the 2024 Republican Party platform vowed to repeal the order that it said hinders AI innovation and added “Republicans support AI development rooted in free speech and human flourishing.” Publicly traded companies associated with artificial intelligence or AI, and other possible AI infrastructure firms include Alphabet (GOOG) (GOOGL), Amazon (AMZN), Nvidia (NVDA), Microsoft (MSFT), Palantir (PLTR), Broadcom (AVGO), Tesla (TSLA), and Intel (INTC).
Valneva Sustained Immune Response Year After Single Chikungunya Vaccination
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to this age group in the U.S.1, Europe, and Canada2. Data from this trial are also expected to support licensure of IXCHIQ® in Brazil, which would be the first potential approval for use in endemic populations.
The one-year VLA1553-321 data showed that a single-dose vaccination induced a high, sustained immune response in an immunogenicity subset of participants who were CHIKV negative at baseline, with a seroresponse rate of 98.3% (232 out of 236 participants) one year after vaccination (Day 360) compared to 99.1% (232 out of 234 participants) after six month3 (Day 180) and 98.8% (248 out of 251 participants) 28 days4,5 after vaccination. The results complement the long-term persistence data previously reported for adults6, confirming a strong and long-lasting antibody response to the vaccine.
Pelosi Buys Alphabet, Amazon Calls While Selling Apple, Nvidia Shares
Nancy Pelosi's latest congressional trading disclosure reveals new bets on tech giants Alphabet (GOOG, GOOGL) and Amazon (NASDAQ:AMZN), while offloading Apple (NASDAQ:AAPL) and Nvidia (NASDAQ:NVDA) shares.
According to the filing, Pelosi purchased 50 call options on Alphabet and Amazon with a $150 strike price and a Jan. 16, 2026, expiration date, each worth between $250,001 and $500,000. The trades took place on Jan. 14, 2025. Meanwhile, she sold 31,600 Apple shares on Dec. 31, 2024, in a transaction valued between $5M and $25M. On the same day, she sold 10,000 Nvidia shares, worth $1M to $5M, but also purchased Nvidia shares worth up to $500,000 on Jan. 14, 2025.
Beyond big tech, Pelosi added Palo Alto Networks (PANW) shares worth up to $5M, Tempus AI (NASDAQ:TEM) shares worth up to $100,000, and Vistra (NYSE:VST) shares worth up to $1M. At 84, Pelosi remains an active market participant, continuing to adjust her portfolio amid shifting economic and tech trends.
https://finance.yahoo.com/news/nancy-pelosi-buys-alphabet-amazon-133922565.html
Sanofi: Opella reaches study milestone for Cialis
Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve this milestone.
AUTs evaluate the use of the medicine under real-world conditions to identify any issues that have not previously been identified and to confirm that consumers can self-diagnose and treat themselves appropriately without the help of a healthcare provider.
https://finance.yahoo.com/news/press-release-opella-reaches-study-060000897.html
Subscribe to:
Posts (Atom)